<DOC>
	<DOC>NCT00603031</DOC>
	<brief_summary>study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.</brief_summary>
	<brief_title>Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Age 1860 years Type1 diabetes diagnosed between 540 years of age Normal weight(BMI 1827), Insulin treatment from time of diagnosis. Severe complications to diabetes Abnormal liver or kidney function Haemoglobin below the lower limit Macroalbuminuria Systemic disease Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>